212Pb-DOTAM-GRPR1
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for 212Pb-DOTAM-GRPR1, covering 2026-03-20 to 2026-03-20. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors [Phase 1]